A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma
| Status: | Terminated |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 9/21/2017 |
| Start Date: | April 2007 |
| End Date: | January 19, 2010 |
A Single-Blind, Randomized, Positive-controlled Study to Compare Monotherapy With an Inhaled Corticosteroid (Mometasone) to Combination Therapy With an Inhaled Corticosteroid + a Long-Acting Bronchodilator (Advair) in Patients With Milder Persistent Asthma
The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate
comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in
control of mild persistent asthma?
The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy
with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50,
when measured by this standard methodology (methacholine bronchoprovocation) in subjects with
mild persistent asthma.
comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in
control of mild persistent asthma?
The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy
with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50,
when measured by this standard methodology (methacholine bronchoprovocation) in subjects with
mild persistent asthma.
Inclusion Criteria:
- subjects 18 to 65 years of age
- a >2 year history of asthma
- FEV1 > 80% for subjects currently using Advair®.
Exclusion Criteria:
- severe asthma
- current smokers
- pregnant or breast-feeding women
- other chronic significant illnesses
We found this trial at
1
site
Click here to add this to my saved trials
